BRPI0814355A2 - Fragmentos de clivagem de imunoglobulina como indicadores de doença e composições para detecção e ligação dos mesmos - Google Patents

Fragmentos de clivagem de imunoglobulina como indicadores de doença e composições para detecção e ligação dos mesmos

Info

Publication number
BRPI0814355A2
BRPI0814355A2 BRPI0814355-2A2A BRPI0814355A BRPI0814355A2 BR PI0814355 A2 BRPI0814355 A2 BR PI0814355A2 BR PI0814355 A BRPI0814355 A BR PI0814355A BR PI0814355 A2 BRPI0814355 A2 BR PI0814355A2
Authority
BR
Brazil
Prior art keywords
cliving
immunoglobulin
fragments
compositions
detection
Prior art date
Application number
BRPI0814355-2A2A
Other languages
English (en)
Inventor
Robert Jordan
Diane D Petrone
Mary Ryan
Original Assignee
Centocor Ortho Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Ortho Biotech Inc filed Critical Centocor Ortho Biotech Inc
Publication of BRPI0814355A2 publication Critical patent/BRPI0814355A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
BRPI0814355-2A2A 2007-08-10 2008-08-04 Fragmentos de clivagem de imunoglobulina como indicadores de doença e composições para detecção e ligação dos mesmos BRPI0814355A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95516207P 2007-08-10 2007-08-10
PCT/US2008/072083 WO2009023457A1 (en) 2007-08-10 2008-08-04 Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such

Publications (1)

Publication Number Publication Date
BRPI0814355A2 true BRPI0814355A2 (pt) 2015-01-27

Family

ID=40351057

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0814355-2A2A BRPI0814355A2 (pt) 2007-08-10 2008-08-04 Fragmentos de clivagem de imunoglobulina como indicadores de doença e composições para detecção e ligação dos mesmos

Country Status (20)

Country Link
US (1) US20090155280A1 (pt)
EP (1) EP2188306B1 (pt)
JP (2) JP5530356B2 (pt)
KR (2) KR101588276B1 (pt)
CN (2) CN103497254B (pt)
AU (1) AU2008287128B2 (pt)
BR (1) BRPI0814355A2 (pt)
CA (1) CA2696011A1 (pt)
DK (1) DK2188306T3 (pt)
EA (1) EA025220B1 (pt)
ES (1) ES2593791T3 (pt)
HU (1) HUE029649T2 (pt)
IL (1) IL203544A (pt)
MX (1) MX2010001616A (pt)
NZ (1) NZ582916A (pt)
PL (1) PL2188306T3 (pt)
PT (1) PT2188306T (pt)
SG (1) SG183701A1 (pt)
WO (1) WO2009023457A1 (pt)
ZA (1) ZA201001689B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8501907B2 (en) * 2007-08-10 2013-08-06 Janssen Biotech, Inc. Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such
NZ623607A (en) 2009-10-23 2016-07-29 Millennium Pharm Inc Anti-gcc antibody molecules and related compositions and methods
AU2010318542B2 (en) 2009-10-29 2015-08-27 Janssen Biotech Inc. Antibody glycosylation variants
US8041225B2 (en) * 2009-12-21 2011-10-18 General Electric Company Contactless infrared data transmission for wind turbines
AU2010363981A1 (en) * 2010-11-19 2013-05-23 Janssen Biotech Inc. Immunoglobulin cleavage fragments vaccine compositions
DK2654780T3 (en) 2010-12-23 2017-04-10 Janssen Biotech Inc ACTIVE PROTEASE-RESISTANT ANTIBODY-FC MUTANTS
KR101820558B1 (ko) 2010-12-23 2018-02-28 유리타 아. 게. 넓은 영역에 나노 구조체를 생산하기 위한 시스템 및 방법
SG11201406855TA (en) * 2012-04-27 2014-11-27 Millennium Pharm Inc Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy
RU2714967C2 (ru) * 2013-12-27 2020-02-21 Чугаи Сейяку Кабусики Кайся Способ очистки антител с низкой изоэлектрической точкой
WO2015154052A1 (en) 2014-04-04 2015-10-08 Mayo Foundation For Medical Education And Research Isotyping immunoglobulins using accurate molecular mass
WO2017053932A1 (en) 2015-09-24 2017-03-30 Mayo Foundation For Medical Education And Research Identification of immunoglobulin free light chains by mass spectrometry
AU2017325022B2 (en) * 2016-09-07 2022-10-13 Mayo Foundation For Medical Education And Research Identification and monitoring of cleaved immunoglobulins by molecular mass
WO2019055634A1 (en) 2017-09-13 2019-03-21 Mayo Foundation For Medical Education And Research IDENTIFICATION AND MONITORING OF A MACROPHAGE APOPTOSIS INHIBITOR
TW201925233A (zh) * 2017-12-07 2019-07-01 日商中外製藥股份有限公司 抗體、用於在樣品中偵測或捕捉多肽的組成物以及在樣品中偵測或捕捉多肽的方法
US20210325380A1 (en) * 2020-04-20 2021-10-21 EnLiSense, LLC Disease diagnostics using a multi-configurable sensing array

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2162863T3 (es) * 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
AUPM322393A0 (en) * 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US7129331B2 (en) * 2000-05-31 2006-10-31 Pestka Biomedical Laboratories, Inc. Phosphorylated polypeptides and uses related thereto
GB0130228D0 (en) * 2001-12-18 2002-02-06 Hansa Medica Ab Protein

Also Published As

Publication number Publication date
KR20100059850A (ko) 2010-06-04
EP2188306B1 (en) 2016-06-29
ZA201001689B (en) 2011-06-29
US20090155280A1 (en) 2009-06-18
EP2188306A4 (en) 2011-03-02
WO2009023457A1 (en) 2009-02-19
CN103497254A (zh) 2014-01-08
ES2593791T3 (es) 2016-12-13
CN103497254B (zh) 2016-12-28
AU2008287128B2 (en) 2013-07-18
KR101588276B1 (ko) 2016-01-26
EA025220B1 (ru) 2016-12-30
NZ582916A (en) 2012-08-31
AU2008287128A1 (en) 2009-02-19
EA201070236A1 (ru) 2010-08-30
JP2014058535A (ja) 2014-04-03
IL203544A (en) 2015-07-30
PL2188306T3 (pl) 2017-01-31
KR20150059813A (ko) 2015-06-02
CN101889021A (zh) 2010-11-17
SG183701A1 (en) 2012-09-27
CA2696011A1 (en) 2009-02-19
JP5530356B2 (ja) 2014-06-25
HUE029649T2 (en) 2017-02-28
CN101889021B (zh) 2016-06-08
EP2188306A1 (en) 2010-05-26
JP2010536037A (ja) 2010-11-25
PT2188306T (pt) 2016-09-13
DK2188306T3 (en) 2016-08-22
MX2010001616A (es) 2010-03-15

Similar Documents

Publication Publication Date Title
BRPI0814355A2 (pt) Fragmentos de clivagem de imunoglobulina como indicadores de doença e composições para detecção e ligação dos mesmos
BRPI0820980A2 (pt) Composições e métodos para detecção de tiabs
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
BR112012001666A2 (pt) composições de proteína rsv f e métodos para fazer as mesmas
BRPI0819909A2 (pt) anticorpos antimesotelina e usos dos mesmos
BRPI0811635A2 (pt) Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos
BRPI0920927A2 (pt) derivados de azaquinolinona e usos dos mesmos
BRPI1008661A2 (pt) derivados e remédios de aminopirazina
BRPI0912198A2 (pt) anticorpos anti-fn14 e usos dos mesmos
BRPI1010024A2 (pt) derivados de aminopirrolidinona e uso dos mesmos
BRPI1009455A2 (pt) anticorpos anti-c40 e usos dos mesmos
BRPI0815588A2 (pt) Compostos de poliorganossiloxano-poliuréia e/ou de poliorganossilo-xano-poliuretano
BRPI0720700A2 (pt) Proteção dos recursos de um sistema operacional
BRPI1013642A2 (pt) derivado de triazina e composição farmacêutica compreendendo o mesmo
BR112012001260A2 (pt) conjugados de epsilon-polilisina e o emprego dos mesmos
BRPI1014099A2 (pt) alvo bioabsorvível para procedimento de diagnóstico ou terapêutico
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
BRPI1008566A2 (pt) métodos e composições para o diagnóstico e tratamento de câncer
BRPI0913656A2 (pt) anticorpos anti-cdh3 marcados com marcador radioisótopo e usos dos mesmos
BRPI1008564A2 (pt) métodos e composições para o dignóstico e tratamento de câncer
BR112012004731A2 (pt) peptídeos derivados de wnt10 e uso dos mesmos
BRPI0813681A2 (pt) Detecção de coproantígeno de nematelminto
BR112012017355A2 (pt) estrutura de telhado e suportes para o mesmo
BRPI0713736A2 (pt) Derivados de tetralina e indano e emprego destes
BRPI0815373A2 (pt) Derivados de ciclo-hexeno e o uso dos mesmos como fragrâncias

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2525 DE 28-05-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.